Body fluid biomarkers for multiple sclerosis - The long road to clinical application

Nature Reviews Neurology

Volumn 11, Issue 10, 2015, Pages 585-596

  Teunissen, Charlotte E ^a   Malekzadeh, Arjan ^a   Leurs, Cyra ^b   Bridel, Claire ^c,d   Killestein, Joep ^b  

^a Neurochemistry Laboratory and Biobank   (Netherlands)

^b Department of Neurology ^*  (United States)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4; BIOLOGICAL MARKER; CHITINASE 3 LIKE PROTEIN 1; CXCL13 CHEMOKINE; HAPTOGLOBIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MICRORNA; MICRORNA 15B; MICRORNA 20A 5P; MICRORNA 22 5P; MICRORNA 223; MICRORNA 26A 5P; MICRORNA 29; NEUROFILAMENT PROTEIN; NEUTRALIZING ANTIBODY; OLIGOCLONAL BAND; PROTEIN; UNCLASSIFIED DRUG;

ADVERSE DRUG REACTION; AXONAL INJURY; BLOOD LEVEL; BODY FLUID; CEREBROSPINAL FLUID LEVEL; CLINICAL PROTOCOL; COHORT ANALYSIS; DISEASE CLASSIFICATION; EARLY DIAGNOSIS; HUMAN; MULTIPLE SCLEROSIS; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT RESPONSE; DISEASE COURSE; METABOLISM;

BIOMARKERS; BODY FLUIDS; DISEASE PROGRESSION; EARLY DIAGNOSIS; HUMANS; MULTIPLE SCLEROSIS; PROGNOSIS;

EID: 84942991379     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2015.173     Document Type: Review

References (137)

1. Stangel, M. et al. The utility of cerebrospinal fluid analysis in patients with multiple sclerosis. Nat. Rev. Neurol. 9, 267-276 (2013).
2. Sawcer, S., Franklin, R. J. & Ban, M. Multiple sclerosis genetics. Lancet. Neurol. 13, 700-709 (2014).
3. Comabella, M. & Montalban, X. Body fluid biomarkers in multiple sclerosis. Lancet. Neurol. 13, 113-126 (2014).
4. Lublin, F. D. et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 83, 278-286 (2014).
5. Lublin, F. D. New multiple sclerosis phenotypic classification. Eur. J. Neurol. 72, 1-5 (2014).
6. Kuhle, J. et al. Conversion from clinically isolated syndrome to multiple sclerosis: a large multicentre study. Mult. Scler. 21, 1013-1024 (2015).
7. Polman, C. H. et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann. Neurol. 69, 292-302 (2011).
8. Dobson, R., Ramagopalan, S., Davis, A. & Giovannoni, G. Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude. J. Neurol. Neurosurg. Psychiatry 84, 909-914 (2013).
9. Petzold, A. Intrathecal oligoclonal IgG synthesis in multiple sclerosis. J. Neuroimmunol. 262, 1-10 (2013).
10. Leone, M. A. et al. Association of genetic markers with CSF oligoclonal bands in multiple sclerosis patients. PLoS ONE 8, e64408 (2013).
11. Tintoré, M. et al. Do Oligoclonal Bands Add Information to MRI in First Attacks of Multiple Sclerosis? Neurology 70, 1079-1083 (2008)
12. Villar, L. M. et al. Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS. Neurology 59, 555-559 (2002).
13. Ferraro, D. et al. Cerebrospinal fluid oligoclonal IgM bands predict early conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome. J. Neuroimmunol. 257, 76-81 (2013).
14. Villar, L. M. et al. Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. J. Clin. Invest. 115, 187-194 (2005).
15. Villar, L. M. Influence of oligoclonal IgM specificity in multiple sclerosis disease course. Mult. Scler. 14, 183-187 (2008).
16. Espiño, M. et al. Assessment of the reproducibility of oligoclonal IgM band detection for its application in daily clinical practice. Clin. Chim. Acta 438, 67-69 (2015).
17. Brettschneider, J. et al. IgG antibodies against measles, rubella, and varicella zoster virus predict conversion to multiple sclerosis in clinically isolated syndrome. PLoS ONE 4, e7638 (2009).
18. Felgenhauer, K. & Reiber, H. The diagnostic significance of antibody specificity indices in multiple sclerosis and herpes virus induced diseases of the nervous system. Clin. Investig. 70, 28-37 (1992).
19. Persson, L. et al. Elevated antibody reactivity to measles virus NCORE protein among patients with multiple sclerosis and their healthy siblings with intrathecal oligoclonal immunoglobulin G production. J. Clin. Virol. 61, 107-112 (2014).
20. Rosche, B. et al. Measles IgG antibody index correlates with T2 lesion load on MRI in patients with early multiple sclerosis. PLoS ONE 7, e28094 (2012).
21. Jarius, S. et al. The intrathecal, polyspecific antiviral immune response: specific for MS or a general marker of CNS autoimmunity? J. Neurol. Sci. 280, 98-100 (2009).
22. Jarius, S. et al. Polyspecific, antiviral immune response distinguishes multiple sclerosis and neuromyelitis optica. J. Neurol. Neurosurg. Psychiatry 79, 1134-1136 (2008).
23. Brecht, I. et al. Intrathecal, polyspecific antiviral immune response in oligoclonal band negative multiple sclerosis. PLoS ONE 7, e40431 (2012).
24. Kaplan, B., Aizenbud, B. M., Golderman, S., Yaskariev, R. & Sela, B. A. Free light chain monomers in the diagnosis of multiple sclerosis. J. Neuroimmunol. 229, 263-271 (2010).
25. Kaplan, B. et al. Free light chain monomer-dimer patterns in the diagnosis of multiple sclerosis. J. Immunol. Methods 390, 74-80 (2013).
26. Senel, M. et al. Cerebrospinal fluid immunoglobulin kappa light chain in clinically isolated syndrome and multiple sclerosis. PLoS ONE 9, e88680 (2014).
27. Desplat-Jégo, S. et al. Quantification of immunoglobulin free light chains in cerebrospinal fluid by nephelometry. J. Clin. Immunol. 25, 338-345 (2005).
28. Presslauer, S., Milosavljevic, D., Brücke, T., Bayer, P. & Hübl, W. Elevated levels of kappa free light chains in CSF support the diagnosis of multiple sclerosis. J. Neurol. 255, 1508-1514 (2008).
29. Goffette, S., Schluep, M., Henry, H., Duprez, T. & Sindic, C. J. Detection of oligoclonal free kappa chains in the absence of oligoclonal IgG in the CSF of patients with suspected multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 75, 308-310 (2004).
30. Presslauer, S. et al. Kappa free light chains: diagnostic and prognostic relevance in MS and CIS. PLoS ONE 9, e89945 (2014).
31. Srivastava, R. et al. Potassium channel KIR4.1 as an immune target in multiple sclerosis. N. Engl. J. Med. 367, 115-123 (2012).
32. Kraus, V. et al. Potassium channel KIR4.1-specific antibodies in children with acquired demyelinating CNS disease. Neurology 82, 470-473 (2014).
33. Nerrant, E. et al. Lack of confirmation of anti-inward rectifying potassium channel 4.1 antibodies as reliable markers of multiple sclerosis. Mult. Scler. 20, 1699-1703 (2014).
34. Brickshawana, A., et al. Investigation of the KIR4.1 potassium channel as a putative antigen in patients with multiple sclerosis: a comparative study. Lancet Neurol. 13, 795-806 (2013).
35. Reindl, M., Di Pauli, F., Rostásy, K. & Berger, T. The spectrum of MOG autoantibody-associated demyelinating diseases. Nat. Rev. Neurol. 9, 455-461 (2013).
36. Aktas, O. Collateral benefit: the comeback of MOG antibodies as a biomarker in neurological practice. J. Neurol. Neurosurg. Psychiatry 86, 243 (2015).
37. Findling, O. et al. Antimyelin antibodies as predictors of disability after clinically isolated syndrome. Int. J. Neurosci. 124, 567-572 (2014).
38. Krumbholz, M. et al. Chemokines in multiple sclerosis: CXCL12 and CXCL13 upregulation is differentially linked to CNS immune cell recruitment. Brain 129, 200-211 (2006).
39. Sellebjerg, F. et al. Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology 73, 2003-2010 (2009).
40. Alvarez, E. et al. CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions. Mult. Scler. 19, 1204-1208 (2013).
41. Khademi, M. et al. Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. Mult. Scler. 17, 335-343 (2011).
42. Khademi, M. et al. Intense inflammation and nerve damage in early multiple sclerosis subsides at older age: a reflection by cerebrospinal fluid biomarkers. PLoS ONE 8, e63172 (2013).
43. Brettschneider, J. et al. The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS). PLoS ONE 5, e11986 (2010)
44. Disanto, G., Morahan, J., Barnett, M., Giovannoni, G. & Ramagopalan, S. The evidence for a role of B cells in multiple sclerosis. Neurology 78, 823-832 (2012).
45. Libreros, S., Garcia-Areas, R. & Iragavarapu-Charyulu, V. CHI3L1 plays a role in cancer through enhanced production of pro-inflammatory/pro-tumorigenic and angiogenic factors. Immunol. Res. 57, 99-105 (2013).
46. Lee, I.-A., Kamba, A., Low, D. & Mizoguchi, E. Novel methylxanthine derivative-mediated anti-inflammatory effects in inflammatory bowel disease. World J. Gastroenterol. 20, 1127-1138 (2014).
47. Bonneh-Barkay, D., Wang, G., Starkey, A., Hamilton, R. L. & Wiley, C. A. In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases. J. Neuroinflammation 7, 34 (2010).
48. Hinsinger, G. et al. Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis. Mult. Scler. http://dx.doi.org/10.1177/1352458514561906.
49. Correale, J. & Fiol, M. Chitinase effects on immune cell response in neuromyelitis optica and multiple sclerosis. Mult. Scler. 17, 521-531 (2011).
50. Comabella, M. et al. Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain 133, 1082-1093 (2010).
51. Canto, E. et al. Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. Brain 138, 918-931 (2015).
52. Cox, M. B. et al. MicroRNAs miR-17 and miR-20a inhibit T cell activation genes and are under-expressed in MS whole blood. PLoS ONE 5, e12132 (2010).
53. Keller, A. et al. Comprehensive analysis of microRNA profiles in multiple sclerosis including next-generation sequencing. Mult. Scler. 20, 295-303 (2014).
54. Siegel, S. R., Mackenzie, J., Chaplin, G., Jablonski, N. G. & Griffiths, L. Circulating microRNAs involved in multiple sclerosis. Mol. Biol. Rep. 39, 6219-6225 (2012).
55. Keller, A. et al. Multiple sclerosis: microRNA expression profiles accurately differentiate patients with relapsing-remitting disease from healthy controls. PLoS ONE 4, e7440 (2009).
56. Junker, A. et al. MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47. Brain 132, 3342-3352 (2009).
57. Teunissen, C. E., Dijkstra, C. & Polman, C. Biological markers in CSF and blood for axonal degeneration. 4, 32-41 (2005).
58. Norgren, N., Rosengren, L. & Stigbrand, T. Elevated neurofilament levels in neurological diseases. Brain Res. 987, 25-31 (2003).
59. Norgren, N. et al. Neurofilament and glial fibrillary acidic protein in multiple sclerosis. Neurology 63, 1586-1590 (2004).
60. Kuhle, J. et al. Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome. J. Neurol. Neurosurg. Psychiatry 86, 273-279 (2015).
61. Teunissen, C. E. et al. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis. Neurology 72, 1322-1329 (2009).
62. Fialová, L. et al. Serum and cerebrospinal fluid light neurofilaments and antibodies against them in clinically isolated syndrome and multiple sclerosis. J. Neuroimmunol. 262, 113-120 (2013).
63. Kuhle, J. et al. A comparative study of CSF neurofilament light and heavy chain protein in MS. Mult. Scler. 19, 1597-1603 (2013).
64. Khalil, M. et al. CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome. Mult. Scler. 19, 436-442 (2013).
65. Fialová, L., Bartos, A., Švarcová, J., Zimova, D. & Kotoucova, J. Serum and cerebrospinal fluid heavy neurofilaments and antibodies against them in early multiple sclerosis. J. Neuroimmunol. 259, 81-87 (2013).
66. Leoni, V. et al. Changes in human plasma levels of the brain specific oxysterol 24S-hydroxycholesterol during progression of multiple sclerosis. Neurosci. Lett. 331, 163-166 (2002).
67. Teunissen, C. et al. Decreased levels of the brain specific 24S-hydroxycholesterol and cholesterol precursors in serum of multiple sclerosis patients. Neurosci. Lett. 347, 159-162 (2003).
68. Van de Kraats, C. et al. Oxysterols and cholesterol precursors correlate to magnetic resonance imaging measures of neurodegeneration in multiple sclerosis. Mult. Scler. 20, 412-417 (2014).
69. Chataway, J. et al. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet 383, 2213-2221 (2014).
70. Lennon, V. A. et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364, 2106-2112 (2004).
71. Weinshenker, B. G. Neuromyelitis optica is distinct from multiple sclerosis. Arch. Neurol. 64, 899-901 (2007).
72. Wingerchuk, D. M. & Weinshenker, B. G. Neuromyelitis optica (Devic's syndrome). Handb. Clin. Neurol. 122, 581-599 (2014).
73. Palace, J., Leite, M. I., Nairne, A. & Vincent, A. Interferon beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titres. Arch. Neurol. 67, 1016-1017 (2010).
74. Barnett, M. H., Prineas, J. W., Buckland, M. E., Parratt, J. D. & Pollard, J. D. Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy. Mult. Scler. 18, 108-112 (2012).
75. Kitley, J. et al. Catastrophic brain relapse in seronegative NMO after a single dose of natalizumab. J. Neurol. Sci. 339, 223-225 (2014).
76. Jarius, S. & Wildemann, B. Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature. Brain Pathol. 23, 661-683 (2013).
77. Bernard-Valnet, R., Liblau, R. S., Vukusic, S. & Marignier, R. Neuromyelitis optica: a positive appraisal of seronegative cases. Eur. J. Neurol. http://dx.doi.org/10.1111/ene.12679.
78. Waters, P. J. et al. Serologic diagnosis of NMO: a multicentre comparison of aquaporin-4-IgG assays. Neurology 78, 665-671 (2012).
79. Jiao, Y. et al. Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology 81, 1197-1204 (2013).
80. Tanaka, M. & Tanaka, K. Anti-MOG antibodies in adult patients with demyelinating disorders of the central nervous system. J. Neuroimmunol. 270, 98-99 (2014).
81. Höftberger, R. et al. Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Mult. Scler. 21, 866-874 (2014).
82. Kitley, J. et al. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 79, 1273-1277 (2012).
83. Sato, D. K. et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 82, 474-481 (2014).
84. Kezuka, T. et al. Relationship between NMO-antibody and anti-MOG antibody in optic neuritis. J. Neuroophthalmol. 32, 107-110 (2012).
85. Brill, L. et al. Increased anti-KIR4.1 antibodies in multiple sclerosis: could it be a marker of disease relapse? Mult. Scler. 21, 572-579 (2014).
86. Quaye, I. K. Haptoglobin, inflammation and disease. Trans. R. Soc. Trop. Med. Hyg. 102, 735-742 (2008).
87. Bai, S. et al. Proteome analysis of biomarkers in the cerebrospinal fluid of neuromyelitis optica patients. Mol. Vis. 15, 1638-1648 (2009).
88. Bai, S. et al. Proteome analysis of haptoglobin in cerebrospinal fluid of neuromyelitis optica. Mol. Biol. Rep. 37, 1619-1625 (2010).
89. Chang, K.-H. et al. Analyses of haptoglobin level in the cerebrospinal fluid and serum of patients with neuromyelitis optica and multiple sclerosis. Clin. Chim. Acta 417, 26-30 (2013).
90. Jiang, S. F. et al. Proteomics comparison of the sera from multiple sclerosis patients and neuromyelitis optica patients. Genet. Mol. Res. 13, 9292-9299 (2014).
91. Sladkova, V., Mares, J., Hlustik, P., Langova, J. & Kanovsky, P. Intrathecal synthesis in particular types of multiple sclerosis. Biomed. Pap. Med. Fac. Univ. Palacky. Olomouc. Czech. Repub. 158, 124-126 (2014).
92. Villar, L. M. et al. Immunoglobulin M oligoclonal bands: biomarker of targetable inflammation in primary progressive multiple sclerosis. Ann. Neurol. 76, 231-240 (2014).
93. Fenoglio, C. et al. Decreased circulating miRNA levels in patients with primary progressive multiple sclerosis. Mult. Scler. 19, 1938-1942 (2013).
94. Bauernfeind, F. et al. NLRP3 inflammasome activity is negatively controlled by miR-223. J. Immunol. 189, 4175-4181 (2012).
95. Lv, X., Jiang, H., Liu, Y., Lei, X. & Jiao, J. MicroRNA-15b promotes neurogenesis and inhibits neural progenitor proliferation by directly repressing TET3 during early neocortical development. EMBO Rep. 15, 1305-1314 (2014).
96. De Stefano, N. et al. Diffuse axonal and tissue injury in patients with multiple sclerosis with low cerebral lesion load and no disability. Arch. Neurol. 59, 1565-1571 (2002).
97. Jasperse, B. et al. N-acetylaspartic acid in cerebrospinal fluid of multiple sclerosis patients determined by gas-chromatography-mass spectrometry. J. Neurol. 254, 631-637 (2007).
98. Teunissen, C. E. et al. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis. Neurology 72, 1322-1329 (2009).
99. Trentini, A. et al. N-Acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis. J. Neurol. 261, 2338-2343 (2014).
100. Magraner, M. J. et al. Brain atrophy and lesion load are related to CSF lipid-specific IgM oligoclonal bands in clinically isolated syndromes. Neuroradiology 54, 5-12 (2012).
101. Villar, L. M. et al. Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis. Ann. Neurol. 53, 222-226 (2003).
102. Villar, L. M. et al. Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS. Neurology 59, 555-559 (2002).
103. Martínez, M. A. et al. Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis. Mult. Scler. 21, 550-561 (2015).
104. Modvig, S. et al. Cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis. Mult. Scler. http://dx.doi.org/10.1177/1352458515574148.
105. Gandhi, R. et al. Circulating microRNAs as biomarkers for disease staging in multiple sclerosis. Ann. Neurol. 73, 729-740 (2013).
106. Salzer, J., Svenningsson, A. & Sundström, P. Neurofilament light as a prognostic marker in multiple sclerosis. Mult. Scler. 16, 287-292 (2010).
107. Gaiottino, J. et al. Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS ONE 8, e75091 (2013).
108. Disanto, G. et al. Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. J. Neurol. Neurosurg. Psychiatry http://dx.doi.org/10.1136/jnnp-2014-309690.
109. Petzold, A. Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations. Brain 125, 1462-1473 (2002).
110. Axelsson, M. et al. Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis. J. Neurol. 258, 882-888 (2011).
111. Polman, C. H. et al. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet. Neurol. 9, 740-750 (2010).
112. Buck, D. et al. Influence of the HLA-DRB1 genotype on antibody development to interferon beta in multiple sclerosis. Arch. Neurol. 68, 480-487 (2011).
113. Hoffmann, S. et al. HLA-DRB1∗0401 and HLA-DRB1∗0408 are strongly associated with the development of antibodies against interferon-β therapy in multiple sclerosis. Am. J. Hum. Genet. 83, 219-227 (2008).
114. Hegen, H. et al. Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development. Mult. Scler. 20, 577-587 (2013).
115. Gibbs, E., Karim, M. E. & Oger, J. Antibody dissociation rates are predictive of neutralizing antibody (NAb) course: a comparison of interferon beta-1b-treated patients with transient versus sustained NAbs. Clin. Immunol. 157, 91-101 (2014).
116. Serana, F. et al. MxA mRNA quantification and disability progression in interferon beta-treated multiple sclerosis patients. PLoS ONE 9, e94794 (2014).
117. Vennegoor, A. et al. Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis. Mult. Scler. 19, 593-600 (2013).
118. Lundkvist, M. et al. Characterization of anti-natalizumab antibodies in multiple sclerosis patients. Mult. Scler. 19, 757-764 (2013).
119. Axtell, R. C. et al. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat. Med. 16, 406-412 (2010).
120. Hartung, H.-P. et al. Interleukin 17F level and interferon β response in patients with multiple sclerosis. JAMA Neurol. 70, 1017-1021 (2013).
121. Hecker, M. et al. MicroRNA expression changes during interferon-beta treatment in the peripheral blood of multiple sclerosis patients. Int. J. Mol. Sci. 14, 16, 087-110 (2013).
122. Liu, X.-F., Luo, Y.-B., Luo, Z.-H. & Yang, H. Biomarker studies in multiple sclerosis: from proteins to noncoding RNAs. Neurochem. Res. 39, 1661-1674 (2014).
123. De Felice, B. et al. Small non-coding RNA signature in multiple sclerosis patients after treatment with interferon-β. BMC Med. Genomics 7, 26 (2014).
124. Bloomgren, G. et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N. Engl. J. Med. 366, 1870-1880 (2012).
125. Calabresi, P. A. et al. The incidence and significance of anti-natalizumab antibodies. Neurology 69, 1391-1403 (2007).
126. Plavina, T. et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann. Neurol. 76, 802-812 (2014).
127. Schwab, N. et al. l-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology 81, 865-871 (2013).
128. Villar, L. M. et al. Lipid-specific IgM bands in CSF associated with a reduced risk of developing PML during treatment with natalizumab. Ann. Neurol. 77, 447-457 (2015).
129. Teunissen, C. et al. Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. Mult. Scler. 19, 1802-1809 (2013).
130. Gnanapavan, S. et al. Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders. Neurology 83, 1210-1216 (2014).
131. Teunissen, C. E., Tumani, H., Engelborghs, S. & Mollenhauer, B. Biobanking of CSF: international standardization to optimize biomarker development. Clin. Biochem. 47, 288-292 (2014).
132. Del Campo, M. et al. Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. Biomark. Med. 6, 419-430 (2012).
133. Vanderstichele, H. et al. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement. 8, 65-73 (2012).
134. Teunissen, C. E. et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 73, 1914-1922 (2009).
135. International Society for Biological and Environmental Repositories [online], http://www.isber.org/.
136. VU Medical Center. Collaboration possibilities on Protein Stability in CSF [online] http://bit.ly/CSF-stability.
137. Andreasson, U. et al. A practical guide to immunoassay method validation. Front. Neurol. http://dx.doi.org/10.3389/fneur.2015.00179.